Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
Press Release - Cellceutix Corporation (CTIX-OTC: BB) |
|
|
We are not dealing with just another cancer drug; we have indications that it is effective against drug-resistant cancers, which is a multibillion dollar market. Most cancer drugs currently out there are just another variation of existing cancer drugs, whether they be another platinum based drug or another Taxol. We, however, have a completely new and novel compound... - Leo Ehrlich, CPA (CTIX) (Interview published May 28, 2010) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
Cellceutix Closing in on Human Trials with Kevetrin for Drug-Resistant Cancers BEVERLY, MA--(Marketwire - 08/24/10) - Cellceutix Corporation (OTC.BB:CTIX - News) is pleased to announce substantial progress on the toxicology studies for Kevetrin™, the Company's compound for the treatment of multi-drug resistant cancers. The Company has now received all data on the study in rats except for the pharmacokinetic data. The Company has also received the bulk of the data from the study in a second animal species. The remaining data is expected within two to three weeks. In preparation for the Investigational New Drug (IND) filing, Cellceutix is engaging additional consultation to move forward towards clinical trials with Kevetrin.
This Press Release contains forward-looking statements that are based on our current expectations, beliefs and assumptions about the industry and markets in which Cellceutix Corporation operates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause Cellceutix's actual results to be materially different from any future results expressed or implied by these statements. Actual results may differ materially from what is expressed in these statements, and no assurance can be given that Cellceutix can successfully implement its core business strategy and improve future earnings. The factors that may cause Cellceutix's actual results to differ from its forward-looking statements include: Cellceutix's current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix's ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.
|
ceocfointerviews.com does not purchase or
make
recommendation on stocks based on the interviews published.